A Case of Docetaxel-Induced Left Ventricular Outflow Tract Obstruction
- PMID: 37719486
- PMCID: PMC10504054
- DOI: 10.7759/cureus.43598
A Case of Docetaxel-Induced Left Ventricular Outflow Tract Obstruction
Abstract
Docetaxel, a taxoid chemotherapy agent, may induce fluid retention. We present a case of metastatic breast cancer in which high output caused by docetaxel-induced fluid retention resulted in heart failure due to left ventricular outflow tract (LVOT) obstruction. A 58-year-old woman presented with exertional dyspnea and anasarca. The jugular venous pressure was elevated, and the carotid pulse was pulsus bisferiens with a spike-and-dome configuration. On auscultation, a mid-late systolic murmur that did not radiate to the neck but increased with the Valsalva maneuver was noted. Echocardiography revealed a left ventricular ejection fraction of 63% with systolic anterior motion (SAM) of the mitral valve, resulting in LVOT obstruction with a resting pressure gradient of 64 mmHg and moderate to severe mitral regurgitation. Treatment with carvedilol, trichlormethiazide, and an increased dose of furosemide gradually improved her symptoms, physical findings, and echocardiographic abnormalities. This case highlights the importance of recognizing high-output heart failure along with LVOT obstruction in patients scheduled to receive docetaxel.
Keywords: docetaxel; fluid retention; heart failure; high-output; left ventricular outflow tract.
Copyright © 2023, Mase et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Docetaxel: a review of its pharmacology and clinical activity. Trudeau ME. https://pubmed.ncbi.nlm.nih.gov/8853517/ Can J Oncol. 1996;6:443–457. - PubMed
-
- Docetaxel: a review of its use in metastatic breast cancer. Lyseng-Williamson KA, Fenton C. Drugs. 2005;65:2513–2531. - PubMed
-
- Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. van Oosterom AT, Schrijvers D, Schriivers D [corrected to Schrijvers D] Anticancer Drugs. 1995;6:356–368. - PubMed
-
- Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. Semb KA, Aamdal S, Oian P. J Clin Oncol. 1998;16:3426–3432. - PubMed
-
- Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. Piccart MJ, Klijn J, Paridaens R, et al. J Clin Oncol. 1997;15:3149–3155. - PubMed
Publication types
LinkOut - more resources
Full Text Sources